Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Disease area: Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Murer (Luzern, Switzerland). Lumacaftor-Ivacaftor combination therapy in Phe508del homozygous CF patients with end-stage lung disease – preliminary results. 1828

Member's Comments

No comment yet.

Related content which might interest you: TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Effect of the type of end-stage lung disease on postoperative evolution of lung transplantation patients Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012 In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis Source: Eur Respir J, 59 (2) 2102380; 10.1183/13993003.02380-2021 Year: 2022 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study Source: International Congress 2017 – Management of COPD Year: 2017 Screening for cystic fibrosis among high risk group patients with chronic lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 340s Year: 2002 Treatment of lung disease in patients with AATD Source: Eur Respir Monogr 2019; 85: 78-92 Year: 2019 Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His Source: ERJ Open Res, 3 (1) 00056-2016; 10.1183/23120541.00056-2016 Year: 2017 Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018 The effect of smoking in end-stage liver disease patients Source: Annual Congress 2010 - Distortions of the respiratory system in the lung function Year: 2010 Better survival outcomes after bilateral lung transplantation compared to single lung transplantation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 347s Year: 2002 Subsequent COPD and lung cancer in patients with autoimmune disease Source: Eur Respir J 2011; 37: 463 Year: 2011 Survival benefit of lung transplantation compared with medical management and pulmonary rehabilitation for patients with end-stage COPD Source: ERJ Open Res, 6 (2) 00177-2019; 10.1183/23120541.00177-2019 Year: 2020 Telomere-Related Gene mutations in a Greek cohort of suspected monogenic pulmonary fibrosis patients Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 A preliminary study on targeted therapies in advanced lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Incidence of MUC5B minor allele in end-stage lung disease and implications for transplantation Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 CF disease progress regarding lung symptoms – a cohort study Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020 Year: 2021